Fundz

Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories

Dec 13, 2024

Contract Type

agreement

MilanBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Newron Pharmaceuticals S.p.A. and EA Pharma Co., Ltd. have entered into a license agreement to develop, manufacture, and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories. The agreement includes an upfront payment of €44 million and financial contributions to Newron’s upcoming Phase III study, with total potential payments of up to €117 million

Company Information

Company

Newron Pharmaceuticals S.p.A. & EA Pharma Ltd

Location

Milan, Lombardy, Italy

About

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. focused on pharmaceutical development.

Related People

Roberto
Senior decision-maker at this company
••••••••@••••••••

See Roberto's verified email →

Filippo
Senior decision-maker at this company
••••••••@••••••••

See Filippo's verified email →

Laura
Senior decision-maker at this company
••••••••@••••••••

See Laura's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Newron Pharmaceuticals S.p.A. & EA Pharma Ltd's next move

Learn about Strategic plan

Newron Pharmaceuticals S.p.A. & EA Pharma Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.